产品详情
文献和实验
相关推荐
Diagnostic Reagents
Instruments
Sequencing Services
Clinical Laboratory
上海伯杰医疗科技有限公司是一家致力于感染性病原体分子诊断试剂研发和应用，深耕于多重荧光PCR诊断试剂和痕量病毒二代测序试剂及相关服务的国家高新技术企业。秉承着赋能医生，提高生命质量的使命，毕业于上海交通大学的三位创始人创建了伯杰医疗，围绕感染性病原体主线，从诊断试剂、诊断仪器、测序服务和医检所服务等多个面提供全套解决方案，为检验科医生及疾控专家提供病原体诊断好工具。
伯杰医疗是一家集研发、生产、销售于一体的医疗器械制造公司，其总部坐落在上海奉贤区凤创谷，拥有试剂研发生产中心、标准生产厂房、仪器研发生产中心和技术服务中心，共占地13000㎡，公司生产车间已通过ISO 13485质量管理体系的认证。公司还拥有两家第三方医学检验实验室，已通过生物安全二级实验室备案，具备新冠和其他病原体核酸检测资质。此外伯杰医疗还在全国设立多家办事处及子公司，以便于更好地服务全国近3000家临床和科研单位客户。
伯杰医疗立足研发，共组建荧光PCR、等温、胶体金、仪器研发、测序服务五大技术平台，依靠强劲的研发实力，公司现已自主开发400多种病原体核酸检测试剂盒、12种核酸提取试剂、5款分子诊断仪器，已取得14项国内医疗器械注册证/备案凭证，其中 III 类医疗器械注册和生产许可6项，I 类医疗器械注册证和生产许可8项。同时，公司积极沉淀研发成果，共申请60余项知识产权，其中发明专利30多件，目前已有9项获得授权。伯杰医疗也积极参加各类比赛，2020年获得上海市科技进步一等奖、全国创新创业大赛金奖，以及其他多项荣誉。其主导或承担的课题多次获得各类专项资金支持，资助金额累计已达5000万。
未来，伯杰医疗将牢记初心不忘使命，深刻践行客户至上、勇于创新、感恩利他的核心价值观，进一步释放科研能量，研发出更多优秀产品，以快赋检，至简未来，在社会各界的大力支持下茁壮成长，回馈社会。
Shanghai BioGerm Medical Technology Co., Ltd (hereinafter referred to as “BioGerm”) was established in March 2017. It is a high-tech company dedicated to the development and application of molecular diagnostic reagents for infectious pathogens, especially multiple fluorescent PCR diagnostic reagents. With the main focus on infectious pathogens, the company provides a complete set of solutions for emergency response of epidemics to reduce the waiting time for outpatients by one hour, so that patients with serious medical problems can receive accurate treatment.
Located in Shanghai Phoenix Creativity Valley, the main body of BioGerm has a 6,000 square meters of clean plant which is used for the development and production of reagent and instrument, used for technical service and standard GMP production.
The company’s wholly-owned medical laboratory is located in Pudong International Medical Park, covering an area of 1,000 square meters, which is already qualified for molecular genetics and microbial testing. It is a registered level 2 biosafety laboratory with the certification in both ISO 9001 and 13485.
BioGerm can quickly respond to this novel coronavirus epidemic in the early stage is also due to the company’s dedication and long-term accumulation in the field of respiratory virus nucleic acid diagnostic reagents and sequencing services. Before the outbreak, more than 400 nucleic acid detection reagents and three different nucleic acid extraction reagents developed by BioGerm have been widely used in most Chinese Center for Disease Control and Prevention. In the early stages of the epidemic, BioGerm took the advantage of emergency R & D and production in the field of respiratory viruses and took the lead in completing the development of the kit, which ensures that the suspected infection is diagnosed in the early stages of the epidemic. Later, the Novel Coronavirus (2019-nCoV) Nucleic Acid Detection Kit（PCR-Fluorescence Probing）was approved by the National Medical Products Administration and was expropriated by the Shanghai Government for epidemic prevention and control.
At present, BioGerm has more than 400 kinds of pathogenic nucleic acid detection kits, including 2019-nCoV, with self-developed nucleic acid extraction reagents, the first generation of the three automatic nucleic acid extraction instrument and the second generation of nucleic acid extraction workstation has been widely used.
The third generation of all-in-one instrument developed by the company will be launched soon, which can truly liberate doctors' hands. In the diagnosis of respiratory tract infections, BioGerm also has various kinds of respiratory multiplex nucleic acid detection kits coming to market, which can cover 95% of respiratory tract infections with flexible combination of detection methods.
Instruments
Sequencing Services
Clinical Laboratory
上海伯杰医疗科技有限公司是一家致力于感染性病原体分子诊断试剂研发和应用，深耕于多重荧光PCR诊断试剂和痕量病毒二代测序试剂及相关服务的国家高新技术企业。秉承着赋能医生，提高生命质量的使命，毕业于上海交通大学的三位创始人创建了伯杰医疗，围绕感染性病原体主线，从诊断试剂、诊断仪器、测序服务和医检所服务等多个面提供全套解决方案，为检验科医生及疾控专家提供病原体诊断好工具。
伯杰医疗是一家集研发、生产、销售于一体的医疗器械制造公司，其总部坐落在上海奉贤区凤创谷，拥有试剂研发生产中心、标准生产厂房、仪器研发生产中心和技术服务中心，共占地13000㎡，公司生产车间已通过ISO 13485质量管理体系的认证。公司还拥有两家第三方医学检验实验室，已通过生物安全二级实验室备案，具备新冠和其他病原体核酸检测资质。此外伯杰医疗还在全国设立多家办事处及子公司，以便于更好地服务全国近3000家临床和科研单位客户。
伯杰医疗立足研发，共组建荧光PCR、等温、胶体金、仪器研发、测序服务五大技术平台，依靠强劲的研发实力，公司现已自主开发400多种病原体核酸检测试剂盒、12种核酸提取试剂、5款分子诊断仪器，已取得14项国内医疗器械注册证/备案凭证，其中 III 类医疗器械注册和生产许可6项，I 类医疗器械注册证和生产许可8项。同时，公司积极沉淀研发成果，共申请60余项知识产权，其中发明专利30多件，目前已有9项获得授权。伯杰医疗也积极参加各类比赛，2020年获得上海市科技进步一等奖、全国创新创业大赛金奖，以及其他多项荣誉。其主导或承担的课题多次获得各类专项资金支持，资助金额累计已达5000万。
未来，伯杰医疗将牢记初心不忘使命，深刻践行客户至上、勇于创新、感恩利他的核心价值观，进一步释放科研能量，研发出更多优秀产品，以快赋检，至简未来，在社会各界的大力支持下茁壮成长，回馈社会。
Shanghai BioGerm Medical Technology Co., Ltd (hereinafter referred to as “BioGerm”) was established in March 2017. It is a high-tech company dedicated to the development and application of molecular diagnostic reagents for infectious pathogens, especially multiple fluorescent PCR diagnostic reagents. With the main focus on infectious pathogens, the company provides a complete set of solutions for emergency response of epidemics to reduce the waiting time for outpatients by one hour, so that patients with serious medical problems can receive accurate treatment.
Located in Shanghai Phoenix Creativity Valley, the main body of BioGerm has a 6,000 square meters of clean plant which is used for the development and production of reagent and instrument, used for technical service and standard GMP production.
The company’s wholly-owned medical laboratory is located in Pudong International Medical Park, covering an area of 1,000 square meters, which is already qualified for molecular genetics and microbial testing. It is a registered level 2 biosafety laboratory with the certification in both ISO 9001 and 13485.
BioGerm can quickly respond to this novel coronavirus epidemic in the early stage is also due to the company’s dedication and long-term accumulation in the field of respiratory virus nucleic acid diagnostic reagents and sequencing services. Before the outbreak, more than 400 nucleic acid detection reagents and three different nucleic acid extraction reagents developed by BioGerm have been widely used in most Chinese Center for Disease Control and Prevention. In the early stages of the epidemic, BioGerm took the advantage of emergency R & D and production in the field of respiratory viruses and took the lead in completing the development of the kit, which ensures that the suspected infection is diagnosed in the early stages of the epidemic. Later, the Novel Coronavirus (2019-nCoV) Nucleic Acid Detection Kit（PCR-Fluorescence Probing）was approved by the National Medical Products Administration and was expropriated by the Shanghai Government for epidemic prevention and control.
At present, BioGerm has more than 400 kinds of pathogenic nucleic acid detection kits, including 2019-nCoV, with self-developed nucleic acid extraction reagents, the first generation of the three automatic nucleic acid extraction instrument and the second generation of nucleic acid extraction workstation has been widely used.
The third generation of all-in-one instrument developed by the company will be launched soon, which can truly liberate doctors' hands. In the diagnosis of respiratory tract infections, BioGerm also has various kinds of respiratory multiplex nucleic acid detection kits coming to market, which can cover 95% of respiratory tract infections with flexible combination of detection methods.
北京美科美生物技术开发有限公司
代理商实名认证
钻石会员
入驻年限：11年
